ADPT (Adaptive Biotechnologies) Inventories, Other: $10.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADPT Adaptive Biotechnologies Corp ADPT
65 GF Score
Price $26.16
GF Value $11.74
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Inventories, Other?

Adaptive Biotechnologies ADPT -0.34% 65 Inventories, Other is $10.5 Mil as of Jun. 2026. GuruFocus rates ADPT with a GF Score™ of 65/100 and a GF Value™ of $11.74 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Adaptive Biotechnologies's other inventories for the quarter that ended in Jun. 2026 was $10.5 Mil.

Adaptive Biotechnologies's quarterly other inventories increased from Dec. 2025 ($9.8 Mil) to Mar. 2026 ($11.2 Mil) but then declined from Mar. 2026 ($11.2 Mil) to Jun. 2026 ($10.5 Mil).

Adaptive Biotechnologies's annual other inventories declined from Dec. 2023 ($14.4 Mil) to Dec. 2024 ($8.4 Mil) but then increased from Dec. 2024 ($8.4 Mil) to Dec. 2025 ($9.8 Mil).

Adaptive Biotechnologies Inventories, Other Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Inventories, Other Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Other
Get a 7-Day Free Trial Premium Member Only 19.26 14.45 14.45 8.44 9.82

Adaptive Biotechnologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.40 9.93 9.82 11.21 10.50
ADPT
65GF Score
Adaptive Biotechnologies Corp ADPT
Inventories, Other is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Frequently Asked Questions Learn more about Inventories, Other →
What does a Inventories, Other of $10.5 Mil mean?
Adaptive Biotechnologies (ADPT) has a Inventories, Other of $10.5 Mil as of Jun. 2026. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Adaptive Biotechnologies and its competitors.
Is Adaptive Biotechnologies' Inventories, Other too high?
Adaptive Biotechnologies' current Inventories, Other is $10.5 Mil. Overall, Adaptive Biotechnologies has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Inventories, Other compare to GRAL and VCYT?
Adaptive Biotechnologies' Inventories, Other of $10.5 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Other for a Medical Diagnostics & Research company?
A good Inventories, Other depends on the Medical Diagnostics & Research industry context. However, Inventories, Other should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Other mean?
A high Inventories, Other can signal that a stock is expensive relative to its fundamentals. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Inventories, Other is $10.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.74, compared to a current price of $26.16 — trading 122.8% above its estimated fair value. The current Inventories, Other is $10.5 Mil. Adaptive Biotechnologies' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Other calculated?
Inventories, Other is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Inventories, Other is $10.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $26.16 is trading 122.8% above its estimated GF Value™ of $11.74. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Inventories, Other: $10.5 Mil
  • GF Value™: $11.74 vs. price of $26.16 (122.8% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
65GF Score

Get the complete analysis for ADPT

Inventories, Other is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.16
Price
$11.74
GF Value